Heidi O’Neill, PhD, DABT has studied the effects of various chemicals as both pharmacological therapeutics that may benefit and as toxicants that may pose a threat to human health for more than 20 years. Her focus has been in the areas of neuropharmacology, developmental neurobiology, inhalation toxicology, and human health risk assessment.

Dr. O’Neill has particular experience in:

•Human health risk assessment of flavoring compounds in oral/food products and inhalation devices;
•Human health risk assessment of solvents, organophosphates, and pesticides;
•Preparation of FDA submissions for consumer products (inhaled and oral nicotine products);
•Providing scientific litigation support;
•Conducting product stewardship assessments for chemical compounds;
•Conducting toxicological evaluations to support extractable/leachable chemicals (E&T) assessment;

Expertise:

Over the last 4 ½ years, Dr. O’Neill has focused on human health risk assessment for consumer products (tobacco products, cannabis vape products, food, and personal care products) as well as in an industrial setting for pharmaceutical products. She also has extensive experience assisting companies with FDA regulatory submissions for tobacco product, both oral and inhaled.  She also has experience providing expert toxicological analyses to support legal cases. Dr. O’Neill has also assisted with developing the basis of an SDS screening system to build a database for go/ no go decisions for worker safety at a large food company. In addition, Dr. O’Neill has expertise in neurotoxicology, assessing how chemical and biological agents negatively impact the nervous system.